ARQ-255 is an alternate formulation of our JAK1 cream (ARQ-252) being investigated as a treatment for alopecia areata.
Janus kinase 1 (JAK1) inhibitor suspension (ARQ-255) is modified to deliver the drug deep into the dermis and is being investigated for the treatment of alopecia areata.
*In vitro data. Clinical efficacy claims cannot be made.
MOA = mechanism of action
1. Strazzulla et al. J Am Acad Dermatol. 2018;78:1-12. 2. Wagner. J Invest Derm Symp Proc. 2015;17:67-69. 3. Fricke and Miteva. Clin Cosmet Investig Dermatol. 2015;8:397-403. 4. Triyangkulsri and Suchonwanit. Drug Des Devel Ther. 2018;12:2323-2335. 5. Data on File. Arcutis Biotherapeutics, Inc.